AbbVie’s EMA Wins for Maviret, Boey & ASCO 2026 Oncology Breakthroughs Propel Global Growth
AbbVie’s new EMA approvals for Maviret and Boey and upcoming ASCO 2026 oncology data spotlight breakthrough treatments in hepatitis C, aesthetics, and cancer therapy.
4 minutes to read








